PSYLLIUM AS A LIPID-LOWERING AGENT: RESULTS OF A MULTICENTER STUDY

DOI: https://doi.org/10.29296/25877305-2018-01-05
Download full text PDF
Issue: 
1
Year: 
2018

S. Levchenko, Candidate of Medical Sciences; I. Komissarenko, MD; et al. A.I. Evdokimov Moscow State University of Medicine and Dentistry

A total of 721 patients aged 19 to 91 years were examined and treated in a multicenter randomized prospective study. The use of psyllium (Mucofalk) in multitargeted therapy was justified in patients with hyperlipidemia, metabolic syndrome, and constipation. Mucofalk was proven to have a lipid-lowering effect in all patient groups; it was demonstrated that the drug could be co-administered with statins for synergistic action in patients at high and very high risk for cardiovascular diseases. Stool was normalized in the majority of patients long treated with Mucofalk. Drug discontinuation was not required in any patient. Twenty-four Mucofalk therapy reduced body mass index by an average of 4.75–9.80% without substantial dietary restrictions in the patients.
Keywords: 
cardiology
hyperlipidemia
metabolic syndrome
constipation
lipid-lowering agents
psyllium
Mukofalk

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Informatsionnyj bjulleten' №317, janvar' 2015 g. http://www.who.int/mediacentre/factsheets/fs317/ru/
  2. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study // Lancet. – 1994; 344: 1383–9.
  3. Saks F., Pfeffer M., Moye L. et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels // N. Engl. J. Med. – 1996; 335: 1001–9.
  4. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // N. Engl. J. Med. – 1998; 339: 1349–57.
  5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high–risk individuals: a randomized placebo-controlled trial // Lancet. – 2002; 360: 7–22.
  6. Sever P., Dahlof B., Poulter N. et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial // Lancet. – 2003; 361: 1149–58.
  7. Rukovodstvo po kardiologii. Uch. pos. v 3 t. Pod red. G.I. Storozhakova, A.A. Gorbachenkova. T. 1 / M.: GEOTAR-Media, 2008; 672 s.
  8. Diagnostika i korrektsija lipidnogo obmena s tsel'ju profilaktiki i lechenija ateroskleroza. Rossijskie rekomendatsii RKO, V peresm., Moskva // Ros. kardiol zhurn. – 2012; 4S1 (96): 2–32.
  9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high—risk individuals: a randomized placebo-controlled trial // Lancet. – 2002; 360: 7–22.
  10. Shepherd L., Blauw G., Murphy M. et al. PROSPER study group. PROspectiveStudy of pravastatin in the elderly at risk. Pravastatin in Elderly individuals at Risk vascular disease (PROSPER): a randomised controlled trial // Lancet. – 2002; 360: 1623–30.
  11. Amarenco P., Bogousslavsky J., Amarenco P. et al. High-dose atorvastatin after stroke or transient ischemic attack // N. Engl. J. Med. – 2006; 355: 549–59.
  12. Colhoun H., Betteridge D., Durrington P. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial // Lancet. – 2004; 364: 685–96.
  13. Kotseva K., Wood D., De Backer G. et al. EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries // Eur. J. Cardiovasc. Prev. Rehabil. – 2009; 16 (2): 121–37.
  14. Susekov A.V., Zubareva M.Ju., Deev A.D. i dr. Osnovnye rezul'taty Moskovskogo Issledovanija po Statinam (Moscow Statin Survey, MSS) // Serdtse. – 2006; 6: 324–8.
  15. Shal'nova S.A., Deev L.D. Uroki issledovanija OSKAR – epidemiologija i osobennosti terapii patsientov vysokogo riska v real'noj klinicheskoj praktike 2005–2006 gg. // Kardiovask. ter. i prof. – 2007; 6 (1): 47–53.
  16. Lukina Ju.V., Poljanskaja Ju.N., Tolpygina S.N. i dr. Izuchenie priverzhennosti lecheniju statinami u patsientov s hronicheskoj ishemicheskoj serdtsa i sootvetstvija gipolipidemicheskoj terapii klinicheskim rekomendatsijam(po dannym registra PROGNOZ IBS) // Profilakt. med. – 2014; 4: 39–43.
  17. Komissarenko I.A., Levchenko S.V., Sil'vestrova S.Ju. i dr. Terapija pri divertikuljarnoj bolezni i giperholesterinemii // Vrach. – 2012; 4: 102–7.
  18. Komissarenko I.A., Levchenko S.V., Gudkova R.B. i dr. Effekty dlitel'nogo primenenija psilliuma pri lechenii bol'nyh divertikuljarnoj bolezn'ju tolstoj kishki // Klin. perspektivy gastroenterol, gepatol. – 2014; 3: 29–36.
  19. Maevskaja E.A., Maev I.V., Kucherjavyj Ju.A. i dr. Otsenka vlijanija laktulozy ili pischevyh volokon na dinamiku pokazatelej lipidnogo profilja u patsientov s funktsional'nym zaporom i nealkogol'nym steatogepatitom // Lechaschij vrach. – 2016; 4: 117–24.
  20. Svistunov A.A., Osadchuk M.A., Butorova L.I. i dr. Sindrom hronicheskogo zapora v praktike terapevta: osobennosti terapii pri sochetannoj patologii // Ter. arh. – 2017; 4: 69–74.
  21. Natsional'nye rekomendatsii po kardiovaskuljarnoj profilaktike // Kardiovask. ter. i profilakt. (Pril. 2). – 2011; 10 (6): 1–64.
  22. Lacy B., Mearin F., Chang L. et al. Bowel Disorders // Gastroenterology. – 2016; 150: 1393–407.
  23. Hubacek J. et al. FTO variant, energy intake, physical activity and basal metabolic rate in Caucasians. The HAPIEE study // Physiological research: Academia Scientiarum Bohemoslovaca. – 2011; 60 (1): 175.
  24. Kuulasmaa K. et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations // Lancet. – 2000; 355 (9205): 675–87.
  25. Ardatskaja M.D.. Klinicheskoe primenenie pischevyh volokon. Metod. posobie / M.: 4TE Art, 2010; 48 s.
  26. Wang Z., Zuberi A., Zhang X. et al. Effects of dietary fibers on weight gain, carbohydrate metabolism, and gastric ghrelin gene expression in mice fed a high-fat diet // Metabolism. – 2007; 56 (12): 1635–42.